Description
BSE lists 15,000 Commercial Papers of Poonawalla Fincorp Limited worth Rs. 750 crores with 91-day maturity, rated CARE A1+ and CRISIL A1+.
Summary
BSE has listed new Commercial Papers issued by POONAWALLA FINCORP LIMITED on private placement basis, effective November 20, 2025. The listing comprises 15,000 securities with a face value of Rs. 5,00,000 each (total Rs. 750 crores), issued at a discount with maturity period of 91 days. The securities carry dual ratings of CARE A1+ and CRISIL A1+, indicating highest safety for short-term instruments.
Key Points
- Issuer: POONAWALLA FINCORP LIMITED
- Security Type: Commercial Paper (private placement)
- Quantity: 15,000 units
- Face Value: Rs. 5,00,000 per unit
- Issue Price: Rs. 4,91,893.50 per unit (discount of Rs. 8,106.50)
- Total Issue Size: Rs. 750 crores
- Scrip Code: 730603
- Scrip ID: PFL191125
- ISIN: INE511C14ZB2
- Credit Rating: CARE A1+, CRISIL A1+
- Market Lot: 1 unit
- Tick Size: 1 paise
- Issuing and Paying Agent: ICICI BANK LTD
Regulatory Changes
No regulatory changes introduced. This is a standard listing notification for debt securities issued under existing regulations governing commercial paper issuances.
Compliance Requirements
- Trading members must trade these securities only in dematerialized form under ISIN INE511C14ZB2
- Trading permitted only in standard denomination of Rs. 5 lakhs and multiples thereof
- Trading members requiring clarifications may contact BSE Debt Department on 22728352/8597/8995/5753/8915
Important Dates
- Allotment Date: November 19, 2025
- Listing Date: November 20, 2025
- Redemption Date: February 18, 2026
- Maturity Period: 91 days
Impact Assessment
Market Impact: Minimal. This is a routine commercial paper listing that provides short-term funding to Poonawalla Fincorp Limited. The instrument is restricted to debt market participants and institutional investors.
Operational Impact: None for equity market participants. Only debt segment trading members dealing in commercial papers are affected.
Investor Impact: The high credit ratings (A1+ from both CARE and CRISIL) indicate strong credit quality, making these instruments suitable for conservative institutional investors seeking short-term deployment with minimal credit risk.
Impact Justification
Routine commercial paper listing with no broader market implications; affects only specific debt market participants